Skip to main
LPCN

Lipocine (LPCN) Stock Forecast & Price Target

Lipocine (LPCN) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lipocine Inc. is advancing its portfolio of proprietary oral drug delivery solutions, with LPCN 1154 showing promising data, including a rapid onset of action and a high remission rate of up to 61% within three days alongside a favorable safety profile. The company is on track to potentially submit a 505(b)(2) new drug application for LPCN 1154, which could significantly enhance its market presence and revenue potential. Despite reporting a minor net loss of $3.2 million, the increased probability of LPCN 1154's approval strengthens the company's growth outlook, signaling a positive trajectory for its financial performance.

Bears say

Lipocine Inc reported a net loss of $3.2 million in the third quarter of 2025, indicating continued financial strain as the company invests in costly research and development efforts. Additionally, the outlook for LPCN 1154 is fraught with uncertainty, as it faces multiple risks including the potential failure in clinical trials, challenges in obtaining regulatory approval, and hurdles in achieving commercial success due to market dynamics. The presence of dilution risk further exacerbates the company's financial challenges, highlighting concerns over long-term investor value and stock performance.

Lipocine (LPCN) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lipocine and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lipocine (LPCN) Forecast

Analysts have given Lipocine (LPCN) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Lipocine (LPCN) has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lipocine (LPCN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.